Impact of chronic kidney disease on the short- and long-term outcomes of laparoscopic gastrectomy for gastric cancer patients

Katsunobu Sakurai*, Naoshi Kubo, Yutaka Tamamori, Naoki Aomatsu, Takafumi Nishii, Akiko Tachimori, Kiyoshi Maeda

Department of Gastroenterological Surgery, Osaka City General Hospital, Osaka, Japan

* m1157473@med.osaka-cu.ac.jp

Abstract

Backgrounds

This study was undertaken to investigate the impact of coexisting chronic kidney disease (CKD) on short- and long-term outcomes of laparoscopic gastrectomy in patients with gastric cancer (GC).

Methods

We reviewed the data of 798 patients treated for GC by laparoscopic gastrectomy. All procedures took place between January 2010 and December 2017. Patients were divided into three groups according to their estimated glomerular filtration rate (eGFR): severe CKD group, 44 patients with eGFR < 45 mL/min/1.73 m²; moderate CKD group, 117 patients with 45 ≤ eGFR < 60; control group, 637 patients with eGFR ≥ 60.

Results

Based on multivariate analysis, severe CKD (eGFR < 45) emerged as an independent predictor of anastomotic leak (Hazard ratio 4.63, 95% confidence interval [CI] 1.62–11.54). The 5-year overall survival (OS) rates by group were 46.3% (severe CKD), 76.6% (moderate CKD), and 81.5% (control). Multivariate analysis likewise identified severe CKD (eGFR < 45) as an independent correlate of poor 5-year OS. The 5-year cancer-specific survival (CSS) rates did not differ significantly by group.

Conclusions

An eGFR value less than 45 mL/min/1.73 m² is a useful factor for predicting both anastomotic leak and 5-year OS in GC patients undergoing laparoscopic gastrectomy. Clinical care to improve eGFR should be reinforced before and after gastrectomy for GC patients with severe CKD.
Introduction

In East Asia, laparoscopic gastrectomy for gastric cancer (GC) is as safe and curative as open gastrectomy and has become the standard procedure for early GC [1, 2]. This procedure has been widely adopted for advanced cancer in recent years, with non-inferior outcomes compared to open gastrectomy [3, 4]. In addition, there have been several reports demonstrating that laparoscopic gastrectomy can be safely performed even in the elderly due to its minimally invasive nature [5, 6]. Thus, laparoscopic gastrectomy for GC is now an essential procedure for surgeons.

Japan has the highest aging rate worldwide, and the elderly population will continue to increase going forward [7, 8]. The elderly often have comorbidities, and the risk of operation and long-term outcomes differ depending on the severity of the comorbidities. Therefore, elucidating the association between the comorbidities and treatment outcomes for patients undergoing laparoscopic gastrectomy will help identify differences in surgical risk among individual patients and determine the appropriate treatment.

In the course of aging, renal function slowly declines in the absence of obvious symptoms. Thus, there are many cancer patients with untreated chronic kidney disease (CKD). As stipulated in various professional guidelines [9–11], classification of CKD currently relies on estimated glomerular filtration rates (eGFRs) as follows: G1, normal or high (eGFR ≥ 90 mL/min/1.73 m²); G2, mildly decreased (eGFR 60–89 mL/min/1.73 m²); G3a, mildly to moderately decreased (eGFR 45–59 mL/min/1.73 m²); G3b, moderately to severely decreased (eGFR 30–44 mL/min/1.73 m²); G4, severely decreased (eGFR 15–29 mL/min/1.73 m²); G5, renal failure (eGFR < 15 mL/min/1.73 m², dialysis indicated).

The impact of CKD on gastrectomy for GC patients is controversial. Some reports have found that the incidence of morbidity correlated with CKD [12, 13]; however, another report found no significant relationship between short- and long-term outcomes and CKD [14]. Moreover, despite the prevalence of laparoscopic gastrectomy for GC, most patients enrolled in these studies underwent open gastrectomy. Thus, it is essential to elucidate the impact of CKD on treatment outcomes, specifically for patients undergoing laparoscopic gastrectomy. In this retrospective study, we investigated the treatment outcomes of such patients, focusing on coexisting CKD and using eGFR as a gauge of renal function.

Methods

Patients and clinical data collection

A total of 798 patients, who underwent laparoscopic gastrectomy for GC at Osaka City General Hospital (Osaka, Japan) between January 2010 and December 2017, were included in this study. Any patients subjected to prior gastrectomy were excluded. Clinicopathologic variables and postoperative complications were extracted from medical records, operative records, and pathology reports. For each patient, retrieval of baseline characteristics included age, gender, body mass index (BMI), serum albumin, comorbidities (diabetes mellitus or ischemic heart disease), tumor data (TNM stage), type of gastrectomy, operative time, recorded blood loss, harvested lymph node count, postoperative complications, and duration of postoperative hospital stay. Informed consent was obtained in the form of opt-out on the hospital’s web-site because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent. The opt-out is a method of publishing information on the web without directly obtaining patient consent for clinical research, and ensuring that patients have the opportunity to refuse. We accessed patient’s medical records from January 2018 to January 2021. All data were fully anonymized before we analyzed them. This study was...
reviewed and approved by the Institutional Review Board (IRB) of Osaka City General Hospital (IRB2006051). The IRB of our hospital approved the use of an opt-out consent mechanism in this study.

Definition
Comorbidity was classified as reported previously [15]. Ischemic heart disease was presumed in patients diagnosed with angina or myocardial infarction or having undergone stent placement, bypass surgery, or medical therapy for coronary disease. Diabetes mellitus was defined as use of oral hypoglycemic drugs or insulin or hemoglobin A1c (HbA1c) level ≥ 6.2, reflecting our institutional criteria. All pathologic terms and classifications were those authorized by the Japanese Gastric Association (14th edition) [16]. Postoperative complications were graded according to Clavien-Dindo (CD) classification [17]. Leakage, pancreatic fistula, intraabdominal abscess and pneumonia of CD grade 2 and beyond were considered customary complications, whereas events of CD grade 3 or more constituted major complications. Overall survival (OS) is defined as the time from the operation date until the date of death. Cancer-specific survival (CSS) refers to the time from the operation until death from tumor relapse only.

Assessment of renal function
We used preoperative eGFR values to assess renal function, based on preoperative blood test data recorded following admission. In accord with previous reports [10], the formulas used to calculate eGFR were: eGFR (mL/min/1.73 m²) = 194 × (serum creatinine)−1.094 × age−0.287 for males; eGFR = (194 × [serum creatinine]−1.094 × age−0.287) × 0.739 for females. In this study, patients were divided into three groups based on the CKD classification as reported previously [11, 12]: G1,2 (control group, eGFR ≥ 60); G3a (moderate CKD group, 45 ≤ eGFR < 60); G3b, 4, and 5 (severe CKD group, eGFR < 45).

Laparoscopic procedures
We began performing laparoscopic gastrectomy at our facility in 1998 and used this procedure mainly for early GC [18, 19]. Since January 2010, we have adopted a laparoscopic approach for advanced GC. The reconstruction of the distal gastrectomy (DG) included the Billroth-II method with Brown’s anastomosis from January 2010 to March 2016. The gastrojejunostomy (GJ) was performed with an extracorporeal procedure from a small incision using a linear stapler from January 2010 to March 2013 and an intracorporeal procedure from April 2013 to March 2016. After April 2016, Billroth-I and II and Roux-en-Y (RY) reconstructions were performed with an intracorporeal procedure using a linear stapler in all parts. The reconstruction of a total gastrectomy (TG) was with an RY reconstruction in all cases. From January 2010 to March 2016, an esophagojejunostomy (EJ) was performed with an extracorporeal procedure from a small incision using a circular stapler. From April 2016, EJ was performed with an intracorporeal procedure using a linear stapler. The reconstruction of the proximal gastrectomy (PG) was double-tract from January 2010 to March 2014. Since April 2014, the double-tract or esophagogastrostomy (EG) was performed as a reconstruction method. EJ was performed with an extracorporeal procedure using a circular stapler from January 2010 to March 2016 and an intracorporeal procedure using a linear stapler since April 2016. EG was performed with an intracorporeal procedure using a linear stapler [20]. Surgeons qualified in the endoscopic surgical skill qualification system in Japan participated in all operations as either an operator or a first assistant.
Statistical analysis

All statistical analyses were performed using standard software (JMP v11; SAS Institute Inc, Cary, NC, USA). Categorical variables were expressed as numerical values and percentages, and group data were compared via $\chi^2$ test or Fisher’s exact test. Continuous variables were expressed as median (minimum-maximum), and differences between the two groups (the control vs. moderate CKD group and the control vs. severe CKD group) were analyzed using Mann-Whitney U test. The uni- and multivariate analysis was performed using a logistic regression model to investigate the factors associated with the incidence of anastomotic leak. The univariate analysis included age, gender, BMI, albumin, co-morbidities (ischemic heart disease, diabetes mellitus and CKD), gastrectomy type, pStage, blood loss and operative time as covariates. All variables with a $p$ value $< 0.10$ in the univariate analysis were entered into a multivariate analysis. Survival curves were generated by Kaplan-Meier method, analyzing differences by log-rank test. Univariate and multivariate hazard ratios (HRs) were calculated via Cox proportional hazard model. Variables that were found to be at $p < 0.10$ on univariate analysis were included in the multivariate analysis. All reported $p$-values were two-sided, setting statistical significance at $p < 0.05$.

Results

Characteristics of patients in each eGFR groups

Clinicopathologic and perioperative characteristics of the GC patients selected for study are shown in Table 1. There were 637 patients in the control group, 117 patients in the moderate CKD group and 44 patients in the severe CKD group. Mean patient age was significantly higher in the moderate and severe CKD group (vs. control) group ($p < 0.001$ for each), but gender ratios and BMI values did not differ significantly by group. In the severe and moderate CKD groups, the serum albumin levels were significantly lower than in the control group ($p < 0.001$, $p = 0.011$). In terms of comorbidities, the incidence of ischemic heart disease was significantly greater in the severe CKD (vs. control) ($p = 0.016$) and diabetes mellitus was likewise significantly greater in the severe CKD (vs. control) group ($p < 0.001$). There were no significant differences in depth of tumor invasion, lymph node metastasis or pathologic staging by group.

Operative findings and short-term outcomes

In type of gastrectomy, the proportion of partial gastrectomy was significantly greater in the severe CKD (vs. control) group ($p = 0.018$). Mean operative time was significantly shorter in the severe CKD (vs. control) group ($p = 0.013$). Mean blood loss estimates or mean counts of harvested lymph nodes did not differ significantly by group. The incidence of anastomotic leak was significantly greater in the severe CKD (vs. control) group ($p < 0.001$). The three groups exhibited similar rates of pancreatic fistula, intraabdominal abscess and pneumonia. Major complications (≥ CD 3) significantly occurred with greater frequency in the severe CKD (vs. control) group ($p = 0.012$). The incidence of in-hospital death was significantly greater in the severe CKD (vs. control) group ($p < 0.001$). Postoperative stays were significantly longer in the moderate and severe CKD (vs. control) group ($p = 0.048$, $p = 0.016$). Postoperative chemotherapy was performed significantly less frequently in patients with severe CKD (vs. control, $p = 0.014$).
Correlation between anastomotic leak and clinical characteristics

The correlation between anastomotic leak and characteristic variables are shown in Table 2. Clinical characteristic variables that significantly correlated with the anastomotic leak were male ($p < 0.001$), CKD ($p = 0.003$), total gastrectomy ($p < 0.001$) and blood loss estimates.
Univariate and multivariate analyses of predicting factors of overall survival (OS) and Cancer-specific survival (CSS)

Univariate and multivariate analytic data for OS are shown in Table 4. Univariate analysis of OS indicated that age, gender, albumin, eGFR (severe CKD), total gastrectomy, depth of tumor, lymph node metastasis, complications (CD ≥ 3) and blood loss estimates (≥ 100 mL) were predictors of OS. In multivariate analysis, age (p < 0.001), eGFR (severe CKD) (p < 0.001), depth of tumor (p < 0.001), lymph node metastasis (p < 0.001) and complications (CD ≥ 3) (p = 0.002) were all independently associated with unfavorable outcomes for patients

BMI body mass index, CKD chronic kidney disease.
Table 3. Uni- and multivariate analysis of the risk factors of anastomotic leakage.

|                          | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                          | HR (95% CI)         | P value               | HR (95% CI)         | P value   |
| Age, years               |                     |                       |                      |
| < 70                     |                     |                       |                      |
| ≥ 70                     | 1.77 (0.88–3.65)    | 0.110                 | 4.47 (1.53–19.08)   | 0.004     |
| Gender                   |                     |                       |                      |
| Female                   | 1                   |                       | 1                     |
| Male                     | 5.77 (2.03–24.23)   | < 0.001               | 4.47 (1.53–19.08)   | 0.004     |
| BMI                      |                     |                       |                      |
| < 22                     | 1                   |                       |                      |
| ≥ 22                     | 1.30 (0.64–2.75)    | 0.479                 |                       |
| Albumin, g/dl            |                     |                       |                      |
| ≥ 3.5                    | 1                   |                       |                      |
| < 3.5                    | 1.63 (0.73–3.41)    | 0.223                 |                       |
| Diabetes mellitus        |                     |                       |                      |
| Absent                   | 1                   |                       |                      |
| Present                  | 1.92 (0.75–4.33)    | 0.161                 |                       |
| Ischemic heart disease   |                     |                       |                      |
| Absent                   | 1                   |                       |                      |
| Present                  | 1.56 (0.37–4.60)    | 0.498                 |                       |
| CKD                      |                     |                       |                      |
| Control                  | 1                   |                       |                      |
| Moderate                 | 1.59 (0.57–3.79)    | 0.351                 | 1.56 (0.55–3.83)     | 0.377     |
| Severe                   | 4.63 (1.62–11.55)   | 0.006                 | 6.46 (2.13–17.74)    | 0.002     |
| Gastrectomy              |                     |                       |                      |
| Partial                  | 1                   |                       |                      |
| Total                    | 3.86 (1.89–7.85)    | < 0.001               | 3.95 (1.75–9.00)     | 0.001     |
| pStage                   |                     |                       |                      |
| 1                        | 1                   |                       |                      |
| 2,3                      | 1.68 (0.83–3.41)    | 0.145                 |                       |
| Blood loss               |                     |                       |                      |
| < 100mL                  | 1                   |                       |                      |
| ≥ 100mL                  | 2.28 (1.11–4.60)    | 0.025                 | 1.12 (0.50–2.44)     | 0.783     |
| Operative time           |                     |                       |                      |
| < 315 min                | 1                   |                       |                      |
| ≥ 315 min                | 1.56 (0.79–3.32)    | 0.196                 |                       |

HR hazard ratio, BMI body mass index, CKD chronic kidney disease.

https://doi.org/10.1371/journal.pone.0250997.t003

Table 4. Uni- and multivariate analyses of factors predicting overall survival (OS).

|                          | Univariate analysis | P value | Multivariate analysis | P value |
|--------------------------|---------------------|---------|-----------------------|---------|
|                          | HR (95% CI)         |         | HR (95% CI)           |         |
| Age, years (≥ 70)        | 2.05 (1.50–2.83)    | < 0.001 | 1.83 (1.31–2.58)      | < 0.001 |
| Gender (Male)            | 1.69 (1.19–2.44)    | 0.003   | 1.36 (0.95–2.00)      | 0.095   |
| Albumin, g/dl (< 3.5)    | 2.32 (1.67–3.19)    | < 0.001 | 1.39 (0.97–1.98)      | 0.072   |
| BMI, kg/m² (< 22)        | 1.10 (0.81–1.51)    | 0.535   | -                     | -       |
| eGFR (Severe CKD)        | 3.68 (2.28–5.65)    | < 0.001 | 3.11 (1.87–4.98)      | < 0.001 |
| Diabetes mellitus        | 1.54 (0.99–2.29)    | 0.053   | 1.09 (0.69–1.65)      | 0.702   |
| Ischemic heart disease   | 1.53 (0.82–2.59)    | 0.169   | -                     | -       |
| Gastrectomy (Total)      | 1.74 (1.23–2.42)    | 0.002   | 1.06 (0.72–1.57)      | 0.780   |
| Tumor depth (pT3,4)      | 3.64 (2.66–5.00)    | < 0.001 | 2.64 (1.82–3.86)      | < 0.001 |
| Lymph node metastasis    | 3.93 (2.86–5.45)    | < 0.001 | 2.48 (1.73–3.58)      | < 0.001 |
| Complication (CD ≥ 3)    | 2.83 (1.82–4.23)    | < 0.001 | 2.11 (1.33–3.22)      | 0.002   |
| Blood loss, mL (≥ 100)   | 1.54 (1.11–2.11)    | 0.010   | 1.11 (0.78–1.60)      | 0.573   |

HR hazard ratio, CI confidence interval, BMI Body mass index, CKD Chronic renal disease, CD Clavien Dindo classification.

https://doi.org/10.1371/journal.pone.0250997.t004
with GC. The hazard ratio (HR) for eGFR (severe CKD) was 3.11 (95% confidence interval [CI], 1.87–4.98). eGFR (severe CKD) was not a predictive factor for CSS by univariate analysis (univariate HR = 2.03; 95% CI = 0.85–4.09; \( p = 0.104 \)); however, pT and pN stage were independent prognostic factors (Table 5).

**Long-term survival rate**

For the patient survival curves, the 5-year OS rates for the groups were as follows: control group, 81.5%; moderate CKD group, 76.6%; severe CKD group, 46.3% (Fig 1). The OS outcomes were significantly worse for the severe CKD group compared to control group (severe CKD vs. control, \( p < 0.001 \)). There was no significant difference in the OS between the control and moderate CKD groups (\( p = 0.245 \)). The respective 5-year CSS rates of the three group were as follows: control, 88.9%; moderate CKD, 88.3%; severe CKD, 78.8% (Fig 2). The outcomes did not differ significantly by group (moderate CKD vs. control, \( p = 0.929 \), severe CKD vs. control, \( p = 0.058 \)).

**Discussion**

In this study, CKD was closely associated with short-term outcomes in GC patients who underwent laparoscopic gastrectomy. Severe CKD (eGFR < 45) was a risk factor for major complications, in-hospital death, and longer hospital stays. In particular, severe CKD (eGFR < 45) emerged as an independent predictor of anastomotic leak. For long-term outcomes, the OS of patients was significantly worse for the severe CKD group than the other two groups; however, the CSS rate did not differ between groups.

Our results indicate that CKD adversely affects the short- and long-term outcomes of GC patients undergoing laparoscopic gastrectomy. Matsumoto et al. reported the outcomes of gastrectomy for GC patients with CKD, in which about 85% of the patients underwent open gastrectomy [12]. In their study, the percentages of major complications (CD ≥ 3) for the different CKD groups were 34.4% (eGFR ≥ 60), 47.3% (30 < eGFR ≤ 60), and 61.2% (eGFR < 30). The incidence of complications was much greater in every CKD grade compared to those in our study. This discrepancy may be the result of the different approaches (laparoscopic vs. open). Because laparoscopic surgery results in less blood loss than open surgery [3,
there would be less change in the intraoperative water balance, which may be beneficial for patients with CKD as it would reduce postoperative tissue edema and maintain peripheral tissue blood flow, reducing complications. However, Wakahara et al. [14] reported that GC patients with CKD have similar complication rates and relapse-free survival rates to GC patients without CKD, indicating that CKD did not affect the short- and long-term outcomes of these patients. Thus, a multi-institutional study is needed to fully elucidate the association between GC patients with CKD and treatment outcomes.

In this study, even with minimally invasive surgery, the incidence of anastomotic leak increased with worsening CKD grade. This incidence rate in the severe CKD group (eGFR < 45) was more than fourfold higher than in the control group. In patients with gastrointestinal cancer, impaired renal function can increase the incidence of anastomotic leak [12, 13]. However, the optimal cutoff value of eGFR for predicting anastomotic leak in patients undergoing laparoscopic gastrectomy is unclear. Tanaka et al. showed that eGFR was an independent risk factor for leakage in patients with clinical T2-4 GC undergoing gastrectomy with D2 lymphadenectomy [13]. Their optimal cutoff for eGFR in predicting anastomotic leak was 63.2, which is far higher than our cutoff value (eGFR 45). One possible explanation is that patients with stage 1 GC disease were excluded in their study, whereas our study was comprised of patients with disease stages 1–3. Another reason may be that most patients enrolled in their study might have undergone open surgery because of advanced GC, although the surgical approach was not described. Different patient characteristics (e.g., surgical approach and

![Overall survival of CKD groups](https://doi.org/10.1371/journal.pone.0250997.g001)
TNM stage) may have also affected the incidence of anastomotic leak. Although there are a few reports that eGFR affects treatment outcome [12, 13], an optimal cut-off value for predicting outcome based on CKD grade has not been discussed. In addition, they include a lot of open gastrectomy. Our results showed that severe CKD (eGFR < 45) significantly increases the rate of anastomotic leak and significantly decreases the overall survival rate. Therefore, we emphasize that GC patients with an eGFR value less than 45 (CKD > G3b) should be treated for CKD both preoperatively and postoperatively.

In this study, 5-year OS differed significantly by CKD group, regardless of their similar rates of TNM stage. The control and moderate CKD groups had similar 5-year OS rates, but the patient outcomes for severe CKD were significantly worse than those of the control. One of our presumptions is that patients in the severe CKD group may not have received sufficient postoperative chemotherapy. Many CKD patients (severe CKD; eGFR < 45) who undergo gastrectomy cannot tolerate continuous chemotherapy. Another reason is that patients with severe CKD (eGFR < 45) had a higher incidence of anastomotic leak than the other two groups. Because postoperative infectious complications have been reported to lead to a poor prognosis [22], the high complication rate in patients with severe CKD may result in a worse survival rate. Furthermore, Foley et al. maintain that patients with CKD are plagued by catabolic conditions that lead to muscle atrophy, with eGFR and sarcopenia showing a single correlation [23]. In our view, many patients with severe CKD (eGFR < 45) have sarcopenia preoperatively, and decreased dietary intake after gastrectomy further worsens their
nutritional status, leading to an increase in deaths from infectious diseases. More work is needed to confirm these hypotheses.

Unfortunately, the ability to improve eGFR before surgery remains challenging. However, there are several approaches that can improve CKD according to clinical practice guidelines, including stopping smoking and excessive drinking and maintaining a proper weight [11, 24]. For diet therapy, salt intake should be limited to 3–6 g/day and protein intake to 0.6–0.8 g/kg/day for CKD classifications greater than G3a. For CKD with hypertension, blood pressure should be maintained at 130–140/80–90 mmHg using antihypertensive drugs. When hemoglobin levels are less than 11 g/dL, administration of an erythropoietin stimulating antagonist is recommended. We believe that these clinical approaches should be reinforced before surgery for severe CKD in GC patients.

As already mentioned, it is common to find that patients with CKD are in catabolic states due to suppression of protein synthesis, and are subject to muscle wasting [9]. Because declines in muscle mass have been shown to negatively impact outcomes of patient with GCs [25, 26], blockade of CKD-induced protein loss may offer a new therapeutic strategy to improve long-term results. In a previous report by Wang et al [9], the expression of myostatin, a negative regulator of skeletal muscle growth, appears to increase in patients with CKD. Inhibition of myostatin is known to increase in IGF-1/insulin/PI3K/Akt intracellular signaling, providing a mechanism for muscle growth. Another benefit of myostatin inhibition is a cited decrease in circulating levels of TNF-α, IL-6, INF-γ and macrophage colony-stimulating factor 1, all of which are associated with loss of muscle mass [27]. Such an approach may be particularly useful for improving outcomes of gastrectomy in patients with GC and CKD.

The present investigation has several limitations. First, this study was a retrospective study based on a limited number of patients. Thus, our findings are not definitive. A multicenter study is assuredly needed for validation. Another issue is that only eGFR was used to gauge renal function. It is essential to include creatinine clearance (CCr) to evaluate exact renal function; however, no CCr data was available. Therefore, the results of this study need to be confirmed by incorporating CCr. Third, postoperative chemotherapy, including regimen and dose, was not considered in the present study. The CKD patients with advanced-stage GC disease may have received chemotherapy at less than the standard dose. Finally, the concept that renal function at one preoperative time point would impact long-term patient outcomes has not been formally corroborated.

Conclusions

Our results indicate that eGFR is a useful tool for predicting the risk of anastomotic leak and OS for GC patients undergoing laparoscopic gastrectomy. This parameter is informative for understanding the surgical risk and long-term outcomes of GC patients. Clinical care to improve eGFR should be reinforced at the time of GC treatment for GC patients with severe CKD.

Supporting information

S1 Table. (XLSX)

Author Contributions

Conceptualization: Katsunobu Sakurai.
Data curation: Katsunobu Sakurai, Naoshi Kubo, Yutaka Tamamori, Naoki Aomatsu, Takafumi Nishii, Akiko Tachimori.

Formal analysis: Katsunobu Sakurai.

Funding acquisition: Katsunobu Sakurai.

Investigation: Katsunobu Sakurai, Naoshi Kubo.

Supervision: Kiyoshi Maeda.

Writing – original draft: Katsunobu Sakurai.

Writing – review & editing: Katsunobu Sakurai, Naoshi Kubo, Yutaka Tamamori, Naoki Aomatsu, Takafumi Nishii, Akiko Tachimori, Kiyoshi Maeda.

References

1. Katai H, Mizusawa J, Katayama H, Morita S, Yamada T, Bando E, et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial. The lancet Gastroenterology & hepatology. 2020; 5(2):142–51. Epub 2019/11/24. https://doi.org/10.1016/S2468-1253(19)30332-2 PMID: 31757656.

2. Kim HH, Han SU, Kim MC, Kim W, Lee HJ, Ryu SW, et al. Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial. JAMA oncology. 2019; 5(4):506–13. Epub 2019/02/08. https://doi.org/10.1001/jamaoncol.2018.6727 PMID: 30730546.

3. Yoshida K, Honda M, Kumamaru H, Kodera Y, Kakeji Y, Hiki N, et al. Surgical outcomes of laparoscopic distal gastrectomy compared to open distal gastrectomy: A retrospective cohort study based on a nationwide registry database in Japan. Annals of gastroenterological surgery. 2018; 2(1):55–64. Epub 2018/06/05. https://doi.org/10.1002/ags3.12054 PMID: 29863131.

4. Hyung WJ, Yang HK, Park YK, Lee HJ, An JY, Kim W, et al. Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2020; Jco2001210. Epub 2020/08/21. https://doi.org/10.1200/JCO.20.01210 PMID: 32816629.

5. Honda M, Kumamaru H, Etoh T, Miyata H, Yamashita Y, Yoshida K, et al. Surgical risk and benefits of laparoscopic surgery for elderly patients with gastric cancer: a multicenter prospective cohort study. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2019; 22(4):845–52. https://doi.org/10.1007/s10120-018-0898-7 PMID: 30539321.

6. Kim SM, Youn HG, An JY. Comparison of Open and Laparoscopic Gastrectomy in Elderly Patients. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2018; 22(S):785–91. https://doi.org/10.1007/s11605-018-3741-x PMID: 29549619.

7. National Institute of population and social security research, Japan http://www.ipss.go.jp/p-info/e/Population%20Statistics.asp. [cited 2020 Sep 3].

8. Ministry of Health LaW. Japan Annual Health, Labour and Welfare Report 2015, UN, World Population Prospects: The 2012 Revision. Highlights and Advance Tables 2015 https://www.mhlw.go.jp/ english/wp/wp-hw9/dl/summary.pdf [cited 2020 Sep 3].

9. Wang XH, Mitch WE. Mechanisms of muscle wasting in chronic kidney disease. Nature reviews Nephrology. 2014; 10(9):504–16. Epub 2014/07/02. https://doi.org/10.1038/nrneph.2014.112 PMID: 24981816.

10. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDOQI). Kidney international. 2005; 67(6):2089–100. Epub 2005/05/11. https://doi.org/10.1111/j.1523-1755.2005.00365.x PMID: 15982252.

11. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2002; 39(2 Suppl 1):S1–266. Epub 2002/03/21. PMID: 11904577.

12. Matsumoto S, Takayama T, Wakatsuki K, Tanaka T, Migita K, Nakajima Y. Short-term and long-term outcomes after gastrectomy for gastric cancer in patients with chronic kidney disease. World journal of
surgery. 2014; 38(6):1453–60. Epub 2014/01/01. https://doi.org/10.1007/s00268-013-2436-4 PMID: 24378553.

13. Tanaka Y, Kanda M, Tanaka C, Kobayashi D, Mizuno A, Iwata N, et al. Usefulness of preoperative estimated glomerular filtration rate to predict complications after curative gastrectomy in patients with clinical T2-4 gastric cancer. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2017; 20(4):736–43. Epub 2016/10/14. https://doi.org/10.1007/s10120-016-0657-6 PMID: 27734274.

14. Wakahara T, Ueno N, Komatsu S, Ashitani H, Tsukida S, Toyokawa A. Outcome of Gastric Cancer Surgery in Patients with Chronic Kidney Disease. Digestive surgery. 2017; 34(3):241–6. Epub 2016/12/13. https://doi.org/10.1159/000452495 PMID: 27941321.

15. Sakurai K, Kubo N, Tamamori Y, Tamura T, Toyokawa T, Tanaka H, et al. Long-term survival estimates in older patients with pathological stage I gastric cancer undergoing gastrectomy: Duocentric analysis of simplified scoring system. Journal of geriatric oncology. 2019. Epub 2019/01/22. https://doi.org/10.1016/j.jgo.2019.01.003 PMID: 30661876.

16. Japanese classification of gastric carcinoma: 3rd English edition. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2011; 14(2):101–12. Epub 2011/05/17. https://doi.org/10.1007/s10120-011-0041-5 PMID: 21573743.

17. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Annals of surgery. 2009; 250(2):187–96. Epub 2009/07/30. https://doi.org/10.1097/SLA.0b013e3181b3ca2 PMID: 19638912.

18. Tanimura S, Higashino M, Fukunaga Y, Osugi H. Hand-assisted laparoscopic distal gastrectomy with regional lymph node dissection for gastric cancer. Surgical laparoscopy, endoscopy & percutaneous techniques. 2001; 11(3):155–60. Epub 2001/07/11. PMID: 11444743.

19. Tanimura S, Higashino M, Fukunaga Y, Osugi H. Laparoscopic distal gastrectomy with regional lymph node dissection for gastric cancer. Surgical endoscopy. 2003; 17(5):758–62. Epub 2003/03/06. https://doi.org/10.1007/s00464-002-8625-0 PMID: 12618942.

20. Yamashita Y, Yamamoto A, Tamamori Y, Yoshii M, Nishiguchi Y. Side overlap esophagogastrectomy to prevent reflux after proximal gastrectomy. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2017; 20(4):728–35. Epub 2016/12/13. https://doi.org/10.1007/s10120-016-0674-5 PMID: 27941321.

21. Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, et al. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). Annals of surgical oncology. 2013; 20(5):1575–83. Epub 2012/10/19. https://doi.org/10.1245/s10434-012-2720-9 PMID: 23076557.

22. Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Annals of surgical oncology. 2013; 20(5):1575–83. Epub 2012/10/19. https://doi.org/10.1245/s10434-012-2720-9 PMID: 23076557.

23. Foley RN, Wang C, Ishani A, Collins AJ, Murray AM. Kidney function and sarcopenia in the United States general population: NHANES III. American journal of nephrology. 2007; 27(3):279–86. Epub 2007/04/19. https://doi.org/10.1159/000101827 PMID: 17440263.

24. Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018. Clinical and experimental nephrology. 2019; 23(1):1–15. Epub 2018/12/07. https://doi.org/10.1007/s10157-018-1648-1 PMID: 30506489.

25. Sakurai K, Kubo N, Tamura T, Toyokawa T, Amano R, Tanaka H, et al. Adverse Effects of Low Preoperative Skeletal Muscle Mass in Patients Undergoing Gastrectomy for Gastric Cancer. Annals of surgical oncology. 2017; 24(9):2712–9. Epub 2017/05/10. https://doi.org/10.1245/s10434-017-5875-6 PMID: 28477088.

26. Zhuang CL, Huang DD, Pang WY, Zhou CJ, Wang SL, Lou N, et al. Sarcopenia is an Independent Predictor of Severe Postoperative Complications and Long-Term Survival After Radical Gastrectomy for Gastric Cancer: Analysis from a Large-Scale Cohort. Medicine. 2016; 95(13):e3164. Epub 2016/04/05. https://doi.org/10.1097/MD.0000000000001364 PMID: 27043677.

27. Zhang L, Rajan V, Lin E, Hu Z, Han HQ, Zhou X, et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2011; 25(5):1653–63. Epub 2011/02/02. https://doi.org/10.1096/fj.10-176917 PMID: 21282204.